Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-04), Optiscan Imaging's 1-Year Sharpe Ratio is 0.32.
Optiscan Imaging (ASX:OIL) 1-Year Sharpe Ratio Explanation
The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
Optiscan Imaging 1-Year Sharpe Ratio Related Terms
ASX:OIL vs COHR, KEYS, GRMN: 1-Year Sharpe Ratio Comparison
For the Scientific & Technical Instruments subindustry, Optiscan Imaging's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Optiscan Imaging 1-Year Sharpe Ratio vs Hardware Industry
For the Hardware industry and Technology sector, Optiscan Imaging's 1-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where Optiscan Imaging's 1-Year Sharpe Ratio falls into.
The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.
Optiscan Imaging (ASX:OIL) has a 1-Year Sharpe Ratio of 0.32 as of Aug. 04, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Optiscan Imaging and its competitors.
Is Optiscan Imaging's 1-Year Sharpe Ratio too high?
Optiscan Imaging's current 1-Year Sharpe Ratio is 0.32. Overall, Optiscan Imaging has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Optiscan Imaging's 1-Year Sharpe Ratio compare to COHR and KEYS?
Optiscan Imaging's 1-Year Sharpe Ratio of 0.32 can be compared against companies in the Hardware industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Hardware company?
A good 1-Year Sharpe Ratio depends on the Hardware industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Optiscan Imaging and its competitors. Optiscan Imaging's current 1-Year Sharpe Ratio is 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Optiscan Imaging stock overvalued right now?
Based on GuruFocus' analysis, Optiscan Imaging (ASX:OIL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.04, compared to a current price of A$0.15 — trading 262.5% above its estimated fair value. The current 1-Year Sharpe Ratio is 0.32. Optiscan Imaging's overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Optiscan Imaging (ASX:OIL), the current 1-Year Sharpe Ratio is 0.32 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Optiscan Imaging (ASX:OIL) Overvalued in 2026?
Based on GuruFocus' analysis, Optiscan Imaging stock appears to be overvalued.
The current stock price of A$0.15 is trading 262.5% above its estimated GF Value™ of A$0.04.
GuruFocus considers Optiscan Imaging to be Significantly Overvalued.
Key valuation signals for ASX:OIL:
1-Year Sharpe Ratio: 0.32
GF Value™: A$0.04 vs. price of A$0.15 (262.5% above fair value)
No single metric tells the full story. See the ASX:OIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Optiscan Imaging Ltd is engaged in the development, manufacture, and commercialization of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications. Its technology offers real-time, 3D, in vivo imaging at the single-cell level, in a non-destructive manner that enables clinicians to make immediate informed decisions. Its products include InVivage, ViewnVivo, and Customisation. Its geographical segments include Australia, Germany, Norway, China, and the United States.
22GF Score
Get the complete analysis for ASX:OIL
1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OIL has been successfully added to your 
